Design of population pharmacokinetic experiments using prior information.

Design of population pharmacokinetic experiments using prior information. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Design of population pharmacokinetic experiments using prior information. Abstract Text:

K Ogungbenro,L Aarons,K Ogungbenro,L Aarons,K Ogungbenro,L Aarons,

A population pharmacokinetic study design is a group of elementary designs each composed of a set of sampling times to be performed in a number of subjects in the design. Design factors such as the number of elementary designs, proportion of subjects in each elementary design, number of samples per subject, and sampling times in the subjects need to be carefully balanced in the design of a study. An optimally designed population pharmacokinetic study will give the best combination of these design factors and involves application of statistical experimental design principles to non-linear population pharmacokinetic models. Information from previous experiments, the literature, and experience in the form of model and parameter estimates are used to design a future study by optimization of a design criterion within some constraints. This work provides a brief background of approaches to the designs of a population pharmacokinetic experiment and a review of optimal design methodologies that have been developed for designing population pharmacokinetic experiments. Computer application programs and software that have been developed together with options available in them are also reviewed.

Design of population pharmacokinetic experiments using prior information. Publishing Authors By Initials

K Ogungbenro,L Aarons,K Ogungbenro,L Aarons,K Ogungbenro,L Aarons,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Design of population pharmacokinetic experiments using prior information. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Xenobiotica; the fate of foreign compounds in biol

VOLUME: 37

Page Numbers: 1311-30

Journal Abbreviation: Xenobiotica

ISSN: 0049-8254

DAY: 30

MONTH: 10

YEAR: 2007

Design of population pharmacokinetic experiments using prior information. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 1306665

Design of population pharmacokinetic experiments using prior information. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Design of population pharmacokinetic experiments using prior information. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Design of population pharmacokinetic experiments using prior information.

AFFILIATION: Centre for Applied Pharmacokinetics Research, School of Pharmacy and Pharmaceutical Sciences, University of Manchester, Manchester, UK.

Country: England

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Xenobiotica

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Design of population pharmacokinetic experiments using prior information Related Publications

• Analytical expressions for combining population pharmacokinetic parameters from different studies.
• Design of population pharmacokinetic experiments using prior information.
• EVALUATION OF FOUR INSECTICIDES AS AEDES AEGYPTI LARVICIDES.
• Ethical analysis of a case of ectopia cordis.
• Ethics, liabilities and licensing to practice.
• Ethics, medicine and society: imperatives for the future.
• General approach to handling nonuniform variance in assay calibration.
• How many subjects are necessary for population pharmacokinetic experiments? Confidence interval approach.
• Incorporating correlation in interindividual variability for the optimal design of multiresponse pharmacokinetic experiments.
• Issues in bioethics. Ethics and professional responsibilities.
• Issues in bioethics. Teaching medical ethics to health professionals.
• Issues in bioethics. Teaching research ethics.
• Measuring adolescent smoking cessation strategies: Instrument development and initial validation.
• Optimisation of sampling windows design for population pharmacokinetic experiments.
• The health care ethics consultant and beneficence in medicine.
• The impact of advanced technology on critical care. Dilemmas in the making.